¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2022-06-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2022-06-11
±³À°ÀÏÀÚ : 2022-06-11
±³À°Àå¼Ò : ´ë±¸ ÀÎÅͺҰí È£ÅÚ 1Ãþ Áñ°Å¿îȦ  
±³À°ÁÖÁ¦ : 2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : °­°æ·¡
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : khfs3@khfs.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï : ÀüÀÓÀÇ, ÀÓ»ó°­»ç(10,000¿ø) /Àü°øÀÇ, °£È£»ç, Á¦¾à»ç, ±× ¿Ü ÀÇ·áÁ¾»çÀÚµé(¹«·á) ÇöÀåµî·Ï : Àü¹®ÀÇ(50,000¿ø), ÀüÀÓÀÇ, ÀÓ»ó°­»ç(20,000¿ø) / Àü°øÀÇ, °£È£»ç, Á¦¾à»ç, ±× ¿Ü ÀÇ·áÁ¾»çÀÚµé(10,000¿ø)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:00~09:15 Diagnostic conundrums in Heart Failure with Preserved Ejection Fraction, is ejection fraction enough?  ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:15~09:30 The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures in normal ejection fraction. Which medications are needed for them? How about weight reduction?  ±èÁöÈñ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:30~09:45 The burden of apical hypertrophic cardiomyopathy with elevated ventricular filling pressures. What should we do for them?  ±è´Ù·¡(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:45~10:00 Who is the Best Candidate for Sodium glucose cotransporter 2 inhibitor in patients with Heart Failure with Preserved Ejection Fraction?  ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 10:00~10:15 Molecular mechanism of heart failure: What is the next therapeutic target?  À̼ö¿ë(ºÎ»êÀÇ´ë) 
Åä·Ð 06-11 Áñ°Å¿îȦ 10:15~10:40 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ06-11 Áñ°Å¿îȦ 10:40~10:50 Coffee Break  () 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 10:50~11:05 Laboratory testing: Gene panels to whole genome sequencing  ±ââ¼®(GCÁö³ð) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:05~11:20 Hypertrophic cardiomyopathy: Monogenetic heart disease: When is a genetic variant disease-causing?  ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:20~11:35 Arrhythmogenic cardiomyopathies  ±è°æÈñ(ÀÎõ ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:35~11:50 Genetics of dilated cardiomyopathy: practical implications  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:50~12:05 (How to find significant genetic variations in rare disease like paraaminohippuric acid?  ÃÖÁ¤¹Î(°í·ÁÀÇ´ë) 
Åä·Ð 06-11 Áñ°Å¿îȦ 12:05~12:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ06-11 Áñ°Å¿îȦ 12:30~13:20 Lunch Time  () 
È޽Ġ06-11 Áñ°Å¿îȦ 13:20~13:30 Break for Quarantine  () 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 13:30~13:45 Influence of surgical techniques and other factors on successful Management Control System outcomes  Á¶¾çÇö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 13:45~14:00 Minimizing and treating complications in left ventricular assist device patients- bleeding to infection  È²È£¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:00~14:15 Strategies to prevent fraility and deconditioning before and after left ventricular assist device  ÀÌÇý¿ø(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:15~14:30 Optimized medical treatment in left ventricular assist device  ÇöÁØÈ£(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:30~14:45 Chronic management in mechanical circulatory support  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 06-11 Áñ°Å¿îȦ 14:45~15:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ06-11 Áñ°Å¿îȦ 15:10~15:30 Coffee Break  () 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 15:30~16:00 Cardiac amyloidosis  ÀüÀº¼®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:00~16:20 Case 1 (È£Èí°ï¶õÀÌ ¾ÇÈ­µÇ¾î ÀÇ·ÚµÈ Ç×ÀÎÁöÁúÁõÈıºÀ» °¡Áø 41¼¼ ¿©ÀÚ È¯ÀÚ)  ±èºÀÁØ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:20~16:40 Case 2 (Severe Infection After Heart Transplantation)  À±¹ÎÀç(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:40~17:00 Case 3 (Myocarditis Combined With Acute Myocardial Infarction)  À̼ö¿¬(ÀÎõ ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 17:00~17:20 Case 4 (&quotAdvanced heart failure with impending End-stage renal disease : early dialysis vs. late dialysis")  Àü°æÇö(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø) 
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 17:20~17:40 Case 5 (µÎ±Ù°Å¸²À¸·Î ³»¿øÇÑ 24¼¼ ³²ÀÚ)  ÀåÁöÈÆ(ÀÎÇÏÀÇ´ë) 
Åä·Ð 06-11 Áñ°Å¿îȦ 17:40~17:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2022-06-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÀÇ»çÇùȸ ÀÇ·á°¨Á¤¿ø Á¦6Â÷ ¿Â¶óÀÎ ÀÇ·á°¨Á¤ ÀÎÁõ±³À°(2ÀÏÂ÷) : 2022-06-12
´ÙÀ½±Û (¿Â¶óÀÎ) 2022³â ´ëÇÑÀ¯¹æ¿µ»óÀÇÇÐȸ Àü°øÀÇ ¿¬¼ö°­Á : 2022-06-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 25 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 25 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 31 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 28 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 26 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 19 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 7 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 7 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 14 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 11 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 5 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 17 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 9 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 19 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 12 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷